Current Cancer Drug Targets

SJR Rank #7,884H-index: 109SJR: 0.726Best quartile: Q2
Journal website: aims, scope and author guidelines
Publisher

Bentham Science Publishers

Country

United Arab Emirates

Type

journal

SJR by Edition

2022202500.20.40.60.8

Subject Categories

  • Drug DiscoveryQ2
  • PharmacologyQ2
  • Cancer ResearchQ3
  • OncologyQ3

Areas: Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Cancer Mechanisms and TherapyCancer, Hypoxia, and MetabolismCancer Research and TreatmentsCancer, Lipids, and MetabolismCancer Immunotherapy and BiomarkersHistone Deacetylase Inhibitors ResearchFerroptosis and cancer prognosisEpigenetics and DNA MethylationCancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs065130195260

Documents per Year

20222025055110165220

Detailed Information

ISSN

1568-0096, 1873-5576

SJR Best Quartile

Q2

Region

Middle East

Citations per Document (2 years)

2.95

References per Document

84.34

Coverage

2001-2026

Scope

Current Cancer Drug Targets aims to cover all the latest and outstanding developments in full spectrum of cancer drug discovery and development, including but not limited to cellular and molecular biology, genomics, proteomics, metabolomics, medicinal chemistry, pharmacology, toxicology, and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters/commentary/perspectives, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel drug targets for human anticancer drug discovery continues to grow, this journal has become essential reading for all biomedical and pharmaceutical scientists involved in drug discovery and development. Its scope covers publications related to prevention, diagnosis and treatment of all types of human cancers in various of basic and translational researches, including cancer etiology, signal transduction, biomarker, chemotherapy, hormone therapy, gene therapy, immunotherapy, radiotherapy, immunotherapy and combination therapy, stem cell, tumor environment, metabolism emphasizing on advanced mechanistic investigations.

Metrics from SCImago Journal Rank 2025. View on SCImago